BIONTECH SE - AMERICAN DEPOSITARY SHARES

Pfizer and BioNTech Initiate Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age Following Request from U.S. FDA

01 Feb 2022 15:27:49 By Nasdaq GlobeNewswire

Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age

25 Jan 2022 05:45:00 By Nasdaq GlobeNewswire

BioNTech and InstaDeep Developed and Successfully Tested Early Warning System to Detect Potential High-Risk SARS-CoV-2 Variants

11 Jan 2022 06:00:00 By Nasdaq GlobeNewswire

BioNTech and Crescendo Biologics Announce Global Collaboration to Develop Multi-specific Precision Immunotherapies

10 Jan 2022 07:00:00 By Nasdaq GlobeNewswire

Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine

05 Jan 2022 05:45:00 By Nasdaq GlobeNewswire

BioNTech to Present at the 40th Annual J.P. Morgan Healthcare Conference

27 Dec 2021 05:45:00 By Nasdaq GlobeNewswire

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 16 Years and Older

09 Dec 2021 11:15:00 By Nasdaq GlobeNewswire

BioNTech to Hold Digital Press Conference to Provide an Update on Omicron Variant

08 Dec 2021 06:15:00 By Nasdaq GlobeNewswire

Pfizer and BioNTech Provide Update on Omicron Variant

08 Dec 2021 05:56:44 By Nasdaq GlobeNewswire

Pfizer and BioNTech Receive Positive CHMP Opinion for COMIRNATY® in Children 5 to under 12 Years of Age in the European Union

25 Nov 2021 06:30:00 By Nasdaq GlobeNewswire

Follow-Up Data from Phase 3 Trial Of Pfizer-BioNTech COVID-19 Vaccine Support Safety and High Efficacy in Adolescents 12 Through 15 Years of Age

22 Nov 2021 05:45:00 By Nasdaq GlobeNewswire

Pfizer and BioNTech Receive Expanded U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster to Include Individuals 18 and Older

19 Nov 2021 07:25:27 By Nasdaq GlobeNewswire

BioNTech Receives FDA Fast Track Designation for its FixVac Candidate BNT111 in Advanced Melanoma

19 Nov 2021 05:30:00 By Nasdaq GlobeNewswire

BioNTech Announces Third Quarter 2021 Financial Results and Corporate Update

09 Nov 2021 05:45:00 By Nasdaq GlobeNewswire

BioNTech to Present New Clinical Data from First-in-Class CAR-T Program BNT211 in Late-breaking Session at 36th SITC Annual Meeting

01 Nov 2021 07:00:00 By Nasdaq GlobeNewswire

Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine in Children Ages 5 Through 11 Years

29 Oct 2021 16:45:00 By Nasdaq GlobeNewswire

Pfizer And BioNTech to Provide U.S. Government an Additional 50 Million Pediatric Doses of COVID-19 Vaccine to Support Further Preparedness for Future Needs

28 Oct 2021 05:58:34 By Nasdaq GlobeNewswire

BioNTech to Report Third Quarter Financial Results and Operational Update on November 9, 2021

27 Oct 2021 06:00:00 By Nasdaq GlobeNewswire

FDA Advisory Committee Votes in Favor of Granting Emergency Use Authorization for the Pfizer-BioNTech Covid-19 Vaccine in Children 5 to <12 Years

26 Oct 2021 17:19:08 By Nasdaq GlobeNewswire

BioNTech Plans to Initiate the Construction of an mRNA Vaccine Manufacturing Facility in Africa in mid-2022

26 Oct 2021 07:00:00 By Nasdaq GlobeNewswire